Glycoproteins have emerged as promising agents in drug delivery due to their potential for targeted delivery. This study developed and evaluated complexes of Pentagamavunon-1 (PGV-1) with glycated bovine serum albumin to enhance cytotoxic effects against cancer cells. Bovine serum albumin nanoparticles (BSA NPs) and glycated BSA nanoparticles [BSA+Lactose (Lac) NPs] were synthesized and complexed with PGV-1. These complexes were characterized by particle size analysis, scanning electron microscopy, transmission electron microscopy, and Fourier transform infrared spectroscopy to confirm their successful synthesis and morphological properties. Cytotoxicity was assessed in HepG2, T47D, and Vero cell lines using MTT assays, while cellular senescence was evaluated by senescence-associated β-galactosidase staining. The results indicated that PGV-1+BSA+Lac NPs significantly increased cytotoxicity in HepG2 and T47D cancer cells compared to free PGV-1, while showing lower toxicity toward non-cancerous Vero cells and demonstrating enhanced selectivity. Furthermore, senescence analysis revealed reduced β-galactosidase activity in Vero cells treated with PGV-1+BSA+Lac NPs relative to free PGV-1, supporting the targeted action of these nanoparticles. In conclusion, PGV-1+BSA+Lac NPs not only improve the delivery efficiency and selectivity of PGV-1 but also present a promising strategy for cancer-specific drug delivery. This research advances the development of glycoprotein-based delivery systems, offering a potential platform for targeted cancer therapies.
Prihapsara F, Meiyanto E, Khadijah, Artanti AN, Hermawan A. Development of pentagamavunon-1 complexes with glycated albumin for targeted drug delivery: Synthesis, characterization, and cytotoxicity in cancer cells. J Appl Pharm Sci. 2025. Online First. http://doi.org/10.7324/JAPS.2025.221096
1. Chen F, Huang G. Application of glycosylation in targeted drug delivery. Eur J Med Chem. 2019;182:111612. doi: https://doi.org/10.1016/j.ejmech.2019.111612
2. Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023;14:1111991. doi: https://doi.org/10.3389/fphar.2023.1111991
3. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems. Polymers (Basel). 2023;15(7):1596. doi: https://doi.org/10.3390/polym15071596
4. Lee MF, Poh CL. Strategies to improve the physicochemical properties of peptide-based drugs. Pharm Res. 2023;40(3):617–32. doi: https://doi.org/10.1007/s11095-023-03486-0
5. Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. JNCI J Natl Cancer Inst. 2019;111(6):538–49. doi: https://doi.org/10.1093/jnci/djz035
6. Jain K, Kesharwani P, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials. 2012;33(16):4166–86. doi: https://doi.org/10.1016/j.biomaterials.2012.02.033
7. Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T, et al. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep. 2019;9(1):1–12. doi: https://doi.org/10.1038/s41598-019-51244-3
8. Meiyanto E, Septisetyani EP, Larasati YA, Kawaichi M. Curcumin analog pentagamavunon-1 (PGV-1) sensitizes Widr cells to 5-fluorouracil through inhibition of NF-κB activation. Asian Pacific J Cancer Prev APJCP. 2018;19(1):49. doi: https://doi.org/10.22034/APJCP.2018.19.1.49
9. Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. Adv Pharm Bull. 2019;9(3):445. doi: https://doi.org/10.15171/apb.2019.053
10. Meiyanto E, Novitasari D, Utomo RY, Susidarti RA, Putri DDP, Kato J. Bioinformatic and molecular interaction studies uncover that CCA-1.1 and PGV-1 differentially target mitotic regulatory protein and have a synergistic effect against leukemia cells. Indones J Pharm. 2022;225–33. doi: https://doi.org/10.22146/ijp.3382
11. Endah E, Wulandari F, Putri Y, Jenie RI, Meiyanto E. Piperine increases Pentagamavunon-1 anti-cancer activity on 4T1 breast cancer through mitotic catastrophe mechanism and senescence with sharing targeting on mitotic regulatory proteins. Iran J Pharm Res IJPR. 2022;21(1). doi: https://doi.org/10.5812/ijpr.123820
12. Huang Y, Hu L, Huang S, Xu W, Wan J, Wang D, et al. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Int J Nanomedicine. 2018;13:8309. doi: https://doi.org/10.2147/IJN.S184379
13. Torres-Pérez SA, Torres-Pérez CE, Pedraza-Escalona M, Pérez-Tapia SM, Ramón-Gallegos E. Glycosylated nanoparticles for cancer-targeted drug delivery. Front Oncol. 2020;10:605037. doi: https://doi.org/10.3389/fonc.2020.605037
14. Teran-Saavedra NG, Sarabia-Sainz JA, Silva-Campa E, Burgara-Estrella AJ, Guzmán-Partida AM, Ramos-Clamont Montfort G, et al. Lactosylated albumin nanoparticles: potential drug nanovehicles with selective targeting toward an in vitro model of hepatocellular carcinoma. Molecules. 2019;24(7):1382. doi: https://doi.org/10.3390/molecules24071382
15. Ledesma-Osuna A, Ramos-Clamont G, Vázquez-Moreno L. Characterization of bovine serum albumin glycated with glucose, galactose and lactose. Acta Biochim Pol. 2008;55(3):491–7. doi: https://doi.org/10.18388/abp.2008_3054
16. Bourassa P, Kanakis CD, Tarantilis P, Pollissiou MG, Tajmir-Riahi HA. Resveratrol, genistein, and curcumin bind bovine serum albumin. J Phys Chem B. 2010;114(9):3348–54. doi: https://doi.org/10.1021/jp9115996
17. Li C, Xie N, Li Y, Liu C, Hou FF, Wang J. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation. Free Radic Biol Med. 2019;130:512–27. doi: https://doi.org/10.1016/j.freeradbiomed.2018.11.006
18. Zai K, Yuzuriha K, Kishimura A, Mori T, Katayama Y. Preparation of complexes between ovalbumin nanoparticles and retinoic acid for efficient induction of tolerogenic dendritic cells. Anal Sci. 2018;34(11):1243–8. doi: https://doi.org/10.2116/analsci.18P252
19. Sponton OE, Perez AA, Carrara CR, Santiago LG. Complexes between ovalbumin nanoparticles and linoleic acid: stoichiometric, kinetic and thermodynamic aspects. Food Chem. 2016;211:819–26. doi: https://doi.org/10.1016/j.foodchem.2016.05.137
20. Weijers M, Visschers RW, Nicolai T. Light scattering study of heat-induced aggregation and gelation of ovalbumin. Macromolecules. 2002;35(12):4753–62. doi: https://doi.org/10.1021/ma0120198
21. Borzova VA, Markossian KA, Chebotareva NA, Kleymenov SY, Poliansky NB, Muranov KO, et al. Kinetics of thermal denaturation and aggregation of bovine serum albumin. PLoS One. 2016;11(4):e0153495. doi: https://doi.org/10.1371/journal.pone.0153495
22. Yadav P, Yadav AB. Preparation and characterization of BSA as a model protein loaded chitosan nanoparticles for the development of protein-/peptide-based drug delivery system. Futur J Pharm Sci. 2021;7:1–9. doi: https://doi.org/10.1186/s43094-021-00345-w
23. Dall’Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci. 2012;17(1):670. doi: https://doi.org/10.2741/3951
24. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24(6):650–4. doi: https://doi.org/10.1097/CCO.0b013e328356da72
25. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol. 2007;5(8):583–97. doi: https://doi.org/10.1038/nrmicro1707
26. Calvaresi EC, Hergenrother PJ. Glucose conjugation for the specific targeting and treatment of cancer. Chem Sci. 2013;4(6):2319–33. doi: https://doi.org/10.1039/C3SC22205E
27. Pastuch-Gawo?ek G, Szreder J, Domi?ska M, Pielok M, Cichy P, Grymel M. A small sugar molecule with huge potential in targeted cancer therapy. Pharmaceutics. 2023;15(3):913. doi: https://doi.org/10.3390/pharmaceutics15030913
28. Wu X-L, Liu L, Wang Q-C, Wang H-F, Zhao X-R, Lin X-B, et al. Antitumor activity and mechanism study of riluzole and its derivatives. Iran J Pharm Res IJPR. 2020;19(3):217. doi: https://doi.org/10.22037/ijpr.2020.1101149
Year
Month